Therapy of lung cancer in China: introducing the special collection

by Jiadi Gan, Wenfeng Fang, Li Zhang
Published 2021-08-01

Research progress in immune checkpoint inhibitors for lung cancer in China

by Jiadi Gan, Yihua Huang, Wenfeng Fang, Li Zhang
Published 2021-07-01

GSK3beta is involved in JNK2-mediated beta-catenin inhibition.

by Dong Hu, Xiuli Bi, Wenfeng Fang, Anjia Han, Wancai Yang
Published 2009-08-01

Transcriptional regulation and biological functions of selenium-binding protein 1 in colorectal cancer in vitro and in nude mouse xenografts.

by Nicole M Pohl, Chang Tong, Wenfeng Fang, Xiuli Bi, Tianhong Li, Wancai Yang
Published 2009-11-01

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment

by Tao Jiang, Qingzhu Jia, Wenfeng Fang, Shengxiang Ren, Xiaoxia Chen, Chunxia Su, Li Zhang, Caicun Zhou
Published 2020-06-01

Gut Microbiota and Lung Cancer: A Mendelian Randomization Study

by Huaqiang Zhou, MD, Jiaqing Liu, MD, Jiayi Shen, MD, Wenfeng Fang, PhD, Li Zhang, MD
Published 2020-09-01

A modifiable risk factors atlas of lung cancer: A Mendelian randomization study

by Jiayi Shen, Huaqiang Zhou, Jiaqing Liu, Yaxiong Zhang, Ting Zhou, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang
Published 2021-07-01

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

by Wenfeng Fang, Yihua Huang, Shaodong Hong, Zhonghan Zhang, Minghui Wang, Jiadi Gan, Wenjing Wang, Honglin Guo, Kai Wang, Li Zhang
Published 2019-06-01

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)

by Zhonghan Zhang, Fan Luo, Yang Zhang, Yuxiang Ma, Shaodong Hong, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang, Hongyun Zhao
Published 2019-11-01

Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes?

by Yaxiong Zhang, Lianpeng Chang, Wenfeng Fang, Yunpeng Yang, Lanjun Zhang, Shaodong Hong, Huaqiang Zhou, Yanfang Guan, Xin Yi, Li Zhang
Published 2019-06-01

Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses.

by Wenhua Liang, Xuan Wu, Shaodong Hong, Yaxiong Zhang, Shiyang Kang, Wenfeng Fang, Tao Qin, Yan Huang, Hongyun Zhao, Li Zhang
Published 2014-01-01

A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China

by Yunpeng Yang, Yuxiang Ma, Jin Sheng, Yan Huang, Yuanyuan Zhao, Wenfeng Fang, Shaodong Hong, Ying Tian, Cong Xue, Li Zhang
Published 2016-04-01

A protective role by interleukin-17F in colon tumorigenesis.

by Zan Tong, Xuexian O Yang, Huichao Yan, Weihuang Liu, Xiaoyin Niu, Yun Shi, Wenfeng Fang, Bing Xiong, Yu Wan, Chen Dong
Published 2012-01-01

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer

by Teng Li, Han Wang, Jiachen Xu, Chengcheng Li, Yudong Zhang, Guoqiang Wang, Yutao Liu, Shangli Cai, Wenfeng Fang, Junling Li, Zhijie Wang
Published 2021-08-01

Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lu...

by Yaxiong Zhang, Jin Sheng, Shiyang Kang, Wenfeng Fang, Yue Yan, Zhihuang Hu, Shaodong Hong, Xuan Wu, Tao Qin, Wenhua Liang, Li Zhang
Published 2014-01-01

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma

by Chen Chen, Yixin Zhou, Xuanye Zhang, Sha Fu, Zuan Lin, Wenfeng Fang, Yunpeng Yang, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang
Published 2020-03-01

Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)

by Ting Zhou, Jianhua Zhan, Wenfeng Fang, Yuanyuan Zhao, Yunpeng Yang, Xue Hou, Zhonghan Zhang, Xiaobo He, Yaxiong Zhang, Yan Huang, Li Zhang
Published 2017-04-01

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study

by Shen Zhao, Shen Zhao, Shen Zhao, Zhen Zhang, Zhen Zhang, Zhen Zhang, Zhen Zhang, Wenfeng Fang, Wenfeng Fang, Wenfeng Fang, Yaxiong Zhang, Yaxiong Zhang, Yaxiong Zhang, Zhonghan Zhang, Zhonghan Zhang, Zhonghan Zhang, Shaodong Hong, Shaodong Hong, Shaodong Hong, Yuxiang Ma, Yuxiang Ma, Yuxiang Ma, Ting Zhou, Ting Zhou, Ting Zhou, Yunpeng Yang, Yunpeng Yang, Yunpeng Yang, Yan Huang, Yan Huang, Yan Huang, Hongyun Zhao, Hongyun Zhao, Hongyun Zhao, Li Zhang, Li Zhang, Li Zhang
Published 2020-11-01

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

by Qiufan Zheng, Shaodong Hong, Yan Huang, Hongyun Zhao, Yunpeng Yang, Xue Hou, Yuanyuan Zhao, Yuxiang Ma, Ting Zhou, Yaxiong Zhang, Wenfeng Fang, Li Zhang
Published 2020-02-01

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-anal...

by Yixin Zhou, Chen Chen, Xuanye Zhang, Sha Fu, Cong Xue, Yuxiang Ma, Wenfeng Fang, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang
Published 2018-12-01